Because compounds for cell surface and intracellular targets are becoming increasingly available, a prospective clinical study is needed to verify the involvement of Lu/BCAM-laminin associated pathways in anti-adhesion strategies in cancer therapies. This evidence concerns the gene LAMB2 and cancer.